SHENZHEN, China. - Monday, September 9th 2013 [ME NewsWire]

(BUSINESS WIRE) ZTE’s Grand Memo LTE is poised to become the first 4G device available for sale in China, after it became the first to be awarded a TD-LTE handset permit by the Ministry of Industry and Information Technology.

The single-SIM, dual stand-by voice solution used by ZTE Grand Memo LTE (Model No: U9815), a quad-band device compatible with the TD-LTE/FDD/TDS/GSM bands, means it is capable of supporting simultaneous high-speed data transmission and high-quality voice calls.

The ZTE Grand Memo LTE is the 4G version of ZTE’s flagship Grand Memo device, offering superior specifications including a 5.7-inch high-definition display with 1280x720 resolution, a 1.5GHz nVidia Tegra3 quad-core processor, 12-core GPU and 13 million pixel camera, supporting 1080P HD video playback and recording. With an ultra-refined display and packing entertainment features including "Home Theater,” the ZTE Grand Memo LTE ... Read more »

BARCELONA, Spain - Monday, September 9th 2013 [ME NewsWire]

(BUSINESS WIRE)--

For media outside the UK, U.S. and Canada

ERS Congress 2013

    Once-daily olodaterol Respimat® maintains lung function improvements in addition to usual care over 24 hours4 and has a rapid onset of action within 5 minutes after the first dose2
    Lung function improvements with once-daily olodaterol Respimat® result in more COPD patients achieving clinically meaningful improvements in quality of life compared to usual care alone3

Data from two 48 week Phase III studies involving more than 3,000 patients show that olodaterol Respimat® in addition to usual care provides statistically significant improvements in lung function vs. usual care alone in patients with COPD (GOLD stages 2-4).1-3

Usual care background therapy included long- and short-acting anticholinergics, short-acting beta agonists, inhaled corticosteroids and x ... Read more »

BARCELONA, Spain - Monday, September 9th 2013 [ME NewsWire]

(BUSINESS WIRE)--

For media outside the U.S., Canada and UK

ERS Congress 2013

    Addition of tiotropium Respimat® provides statistically significant and clinically relevant improvement in asthma control in symptomatic asthma patients receiving ICS† therapy2
    New phase III data presented for the first time demonstrate the efficacy of tiotropium in asthma patients receiving ICS therapy.2 These results add to evidence from the on-going Phase III trial programme that had shown efficacy and safety of tiotropium in patients who remained symptomatic despite treatment with at least ICS/LABA‡3
    At least 40% of asthma patients remain symptomatic despite current standard treatment options and may experience asthma exacerbations (attacks)4

In patients with symptomatic asthma despite moderate-dose maintenance ICS therapy, the addition of tiotro ... Read more »

BANGALORE, India - Monday, September 9th 2013 [ME NewsWire]

(BUSINESS WIRE) Wipro Ltd., (NYSE:WIT), a leading global information technology, consulting and outsourcing company today announced the launch of a range of information technology (IT) products for the aviation industry.

The aviation IT product portfolio comprises of two categories of solutions: enterprise and mobility solutions. Enterprise solutions include products for crew management, route profitability analysis, loyalty management, inflight catering, aircraft maintenance planning and crisis management. Mobility solutions include products for pilots, cabin crew and flight dispatchers.

The extensive product portfolio aims to address critical airline business functions, which have a direct bearing on service quality, operational efficiency and strategic decision making. These products provide competitive advantage to an airline through comprehensive functional features complimented by open technology pla ... Read more »